These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17491693)

  • 1. Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach.
    Bresson D; von Herrath M
    Rev Diabet Stud; 2005; 2(4):187-9; discussion 190-1. PubMed ID: 17491693
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigenic modulation - a major mechanism of antibody action.
    Chatenoud L; Bach JF
    Immunol Today; 1984 Jan; 5(1):20-5. PubMed ID: 25291172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive therapy of autoimmune diseases.
    Bach JF
    Trends Pharmacol Sci; 1993 May; 14(5):213-6. PubMed ID: 8212318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed anti-CD3 therapy in a mouse heart transplant model induced tolerance and long-term survival of allograft: achieving tolerance.
    Vudattu NK; Herold KC
    Immunotherapy; 2013 Nov; 5(11):1173-6. PubMed ID: 24188671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
    van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
    Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
    Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
    Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.
    Kuhn C; Weiner HL
    Immunotherapy; 2016 Jul; 8(8):889-906. PubMed ID: 27161438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo.
    Ren H; Li J; Liu JJ; Guo HL; Jiang T
    Asian Pac J Cancer Prev; 2012; 13(6):2795-8. PubMed ID: 22938461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
    Yang SC; Fry KD; Grimm EA; Roth JA
    J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A future for CD3 antibodies in immunotherapy of type 1 diabetes.
    Chatenoud L
    Diabetologia; 2019 Apr; 62(4):578-581. PubMed ID: 30612137
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial.
    Halota W; Ferenci P; Kozielewicz D; Dybowska D; Lisovoder N; Samira S; Shalit I; Ellis R; Ilan Y
    J Viral Hepat; 2015 Aug; 22(8):651-7. PubMed ID: 25412903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
    Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
    Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J; Demanet C; Moser M; Leo O; Thielemans K
    J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
    Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
    Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.